Upregulation of ABLIM1 Differentiates Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma and Both Colorectal and Pancreatic Adenocarcinoma Liver Metastases

  • 0Institute of Pathology, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.

|

|

Summary

This summary is machine-generated.

This study investigated gene expression in liver cancers, finding actin-binding LIM protein 1 (ABLIM1) is upregulated in cholangiocarcinoma, suggesting it as a potential biomarker for differentiating this cancer from others.

Area Of Science

  • Oncology
  • Molecular Biology
  • Genetics

Background

  • Altered gene expression in cancers offers potential for improved diagnostics and differentiation of primary and metastatic liver cancers.
  • Investigated expression of protein-coding genes (RNF135, EFNB2, RNF125, HOXC4, ABLIM1, OSMR) and lncRNAs (PROX1-AS1, LIFR-AS1).
  • Examined expression in hepatocellular carcinoma, cholangiocarcinoma, colorectal liver metastases, and pancreatic ductal adenocarcinoma liver metastases.

Purpose Of The Study

  • To investigate and compare the expression of specific genes and lncRNAs in various primary and metastatic liver cancers.
  • To identify potential diagnostic biomarkers for differentiating between different types of liver malignancies.

Main Methods

  • Analysis of 149 formalin-fixed, paraffin-embedded samples from 80 patients.
  • RNA isolation, quantification, reverse transcription, and preamplification followed by real-time qPCR.
  • Gene expression analysis using the ∆∆Cq method, AmiCA, and UCSC Xena platforms.

Main Results

  • Differential gene and lncRNA expression observed between primary tumors and healthy tissues for all investigated markers.
  • Downregulation of RNF135 in hepatocellular carcinoma and OSMR in colorectal liver metastases.
  • Upregulation of HOXC4 in cholangiocarcinoma and a significant upregulation of ABLIM1 in cholangiocarcinoma compared to other liver cancers and healthy tissue.

Conclusions

  • Understanding gene expression differences is crucial for diagnosing and differentiating healthy tissues from primary and metastatic liver cancers.
  • Altered gene expression, particularly ABLIM1, shows potential as a diagnostic biomarker for cholangiocarcinoma.
  • Highlights the utility of molecular markers in improving liver cancer diagnostics.